NT-PGC1-α Promotes Hepatic Lipid Metabolism Without Increasing Gluconeogenesis | 14801
ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 1407

Journal of Obesity & Weight Loss Therapy received 1407 citations as per google scholar report

Journal of Obesity & Weight Loss Therapy peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • Centre for Agriculture and Biosciences International (CABI)
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • CABI full text
  • Cab direct
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • University of Bristol
Share This Page

NT-PGC1-α promotes hepatic lipid metabolism without increasing gluconeogenesis

2nd International Conference and Exhibition on Obesity & Weight Management

Qiang Xiao-Yan

ScientificTracks Abstracts: J Obes Weight Loss Ther

DOI: 10.4172/2165-7904.S1.010

PGC-1α (PPARγcoactivator 1α) can promote the transcription of related target genes by interaction with many nuclear receptors. In muscle cells and adipocytes, PGC-1α functions as glucose and fat metabolism promotor. NT-PGC1-α, an isomer of PGC-1α is reported by Zhang for the first time in 2009. Since it lacks the structural domain to interact with FOXO1, which facilitates gluconeogenesis, we came up with a new assumption which is that NT-PGC-1α can enhance fatty acid oxidation in liver, yet has no influence on hepatic gluconeogenesis. By the overexpression of NT-PGC-1α in hepatic cell system HepG2 and L02, it was proved that NT-PGC-1α cannot promote the expression of PEPCK (phosphoenolpyruvate carboxykinase, a key enzyme in gluconeogenesis process) and the hepatic production of glucose, but sharply induced the expression of CPT1A (carnitine palmitoyltransferase 1A, a key enzyme in fatty acid oxidation). Mouse primary hepatocytes induced by palmitate or FGF21 showed notably increased expression of NT-PGC-1α. We then treated mice models of alcoholic fatty liver with resveratrol, and the expression of NT-PGC-1α increased remarkably. This showed that NT-PGC-1α is involved in the process of resveratrol regulating hepatic fatty acid metabolism and proved that NT-PGC-1α participate in hepatic fatty acid metabolism in animals. In this case, the relation between NT-PGC-1α and hepatic fatty acid metabolism is discussed in cells and in animals, and has proved that NT-PGC-1α can enhance fatty acid oxidation in liver, yet has no influence on hepatic gluconeogenesis. According to these findings, NT-PGC-1α could be a new target in obesity or type 2 diabetic treatment.
Qiang Xiao-Yan received her bachelor?s degree in Bioengineering at China Pharmaceutical University in 2010. With 2-years school-enterprise training, she finished her master?s degree in advance in 2012. She is currently working as a Ph.D. student in Biochemical Pharmacy at China Pharmaceutical University. To date, she has published several papers in state core journals in China.